Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Sees Significant Decrease in Short Interest

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) saw a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 223,898 shares, a decline of 73.3% from the July 30th total of 839,994 shares. Based on an average daily trading volume, of 903,947 shares, the short-interest ratio is presently 0.2 days. Approximately 1.6% of the company’s stock are short sold.

Matinas Biopharma Stock Performance

Shares of MTNB traded up $0.00 during trading hours on Thursday, hitting $0.20. 810,866 shares of the company were exchanged, compared to its average volume of 2,159,492. The company has a market cap of $2.94 million, a PE ratio of -0.17 and a beta of 1.76. The firm’s 50 day moving average is $0.40 and its 200-day moving average is $0.55. Matinas Biopharma has a 52 week low of $0.18 and a 52 week high of $2.14.

Matinas Biopharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.21) earnings per share for the quarter.

Hedge Funds Weigh In On Matinas Biopharma

An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC bought a new stake in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is currently owned by hedge funds and other institutional investors.

Matinas Biopharma Company Profile

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.